The Karnataka Medical Supplies Corporation Limited (KSMSCL) finds itself at the centre of a major controversy, with allegations of corruption and financial mismanagement regarding a tender for the procurement of Vitamin C chewable tablets. Despite widespread concern and multiple warnings, the state government has been accused of failing to address the issue, leading to potential financial losses of crores of rupees. State Principal Secretary Harsha Gupta’s letter highlighting the problem appears to have been ignored, raising serious questions about the transparency and accountability of the state administration.
The issue revolves around KSMSCL’s tender for the purchase of Vitamin C tablets worth Rs 44 crore, which was intended to support public health initiatives. The corporation’s decision to conduct a single-tender process without inviting competitive bids has sparked outrage, with critics alleging that the tender favoured a specific company—Bajaj Health Care Limited. Despite several extensions, no other companies participated in the tender, leading to suspicions of foul play.
The terms of the tender are alleged to have been manipulated to suit Bajaj Health Care, allowing the company to quote a significantly higher price than what it had offered in other states. While Bajaj quoted Rs 69 per unit for Karnataka, the same company had quoted just Rs 42.56 per unit for Kerala, leading to a price difference of Rs 26.44 per unit. This discrepancy alone is estimated to cost the state exchequer Rs 17.69 crore.
A comparative analysis of prices offered by Bajaj Health Care in other states reveals just how inflated the Karnataka tender was:
- Uttar Pradesh: The price per tablet was 29 paise, which is Rs 40 less per unit than the Karnataka rate. This disparity suggests a potential loss of Rs 26.76 crore.
- Rajasthan: The price was Rs 41.93 per unit, Rs 27.03 lower than in Karnataka, leading to a projected loss of Rs 18.11 crore.
- Orissa: The rate was Rs 39 per unit, Rs 30 cheaper than Karnataka’s rate, indicating a loss of Rs 20.07 crore.
- Jammu and Kashmir: The price stood at Rs 47 per unit, Rs 20 less than the Karnataka rate, with an estimated loss of Rs 14.71 crore.
These figures suggest that Karnataka could incur a collective loss of more than Rs 90 crore owing to the inflated prices in the tender, sparking accusations of gross negligence and corruption.
The issue gained public attention after media reports highlighted the irregularities in the tender process. Advocate Prashant Methal formally complained to Health and Family Welfare Minister Dinesh Gundurao on July 17, 2024. Following this, Minister Gundurao directed KSMSCL officials to investigate the matter and take action on July 24, 2024. Despite these orders, no substantial action has been taken, and the matter remains unresolved.
Principal Secretary Harsha Gupta also intervened, writing a letter to the Commissioner of the Health Department on August 12, 2024, instructing them to review the tender process and take appropriate action. However, sources reveal that the letter was largely ignored, and no steps were taken to cancel or review the tender. Critics argue that this deliberate inaction points to a cover-up by officials and a possible attempt to protect those involved.
The tender process has come under severe criticism for its lack of transparency. The conditions for the tender restricted participation to online payments only, preventing other companies from offering bank guarantees and effectively limiting competition. Furthermore, the tender removed the requirement for sample submissions from companies, raising questions about the quality and authenticity of the products being procured.
There were also discrepancies in the price estimates. In May 2023, the same Vitamin C tablets were purchased at Rs 52.25 per unit. However, the latest tender raised the price to Rs 67 per unit, a difference of ₹14.75. This inexplicable increase in price over 8 months has only added to the concerns of corruption and favouritism.
When asked about these issues, Managing Director Chidananda Watare attempted to downplay the controversy, stating that only the financial bid had been opened and the process was still ongoing. He further claimed that there were no violations and that the rates were determined based on the Karnataka Transparency in Public Procurement (KTPP) Act. However, these statements have failed to quell suspicions, as critics point out that the terms set by the technical committee appeared to favour Bajaj Health Care from the beginning.
The controversy has brought to light serious flaws in the procurement processes within the Karnataka Medical Supplies Corporation. By continuing with a single-tender process without re-inviting bids, the corporation violated basic principles of fair competition and allowed for potential favoritism, leading to significant financial losses. Despite multiple reports, complaints, and directives, the state government has not taken adequate steps to address these irregularities, suggesting a systemic failure to tackle corruption.
Critics have called for a thorough investigation to uncover how the inflated tender rates were approved and to identify the officials responsible. There are demands for stricter enforcement of procurement rules and greater transparency in government contracts to prevent similar incidents in the future. The Karnataka government’s inaction has raised suspicions of collusion, leading to widespread calls for accountability and reform.
The controversy has also sparked a political backlash, with opposition leaders accusing the ruling party of turning a blind eye to corruption. They have questioned why the government, which claims to promote transparency and good governance, has not acted against the officials involved.
Minister Dinesh Gundurao’s silence on the issue has been particularly criticized, with many asking whether there was a deliberate attempt to cover up the scandal. As public outrage grows, the government will likely face increasing pressure to address the allegations and take action against those responsible.
The Karnataka Medical Supplies Corporation’s alleged mishandling of the Vitamin C tablet tender has exposed serious flaws in the state’s procurement processes, raising concerns about corruption and financial mismanagement. Despite clear evidence of inflated prices and favourable treatment, the government’s failure to act has allowed the issue to fester.
Comments